D-Risk Investing Podcast

Oklo Inc. is making a play to become a revolutionary force in nuclear energy, announcing a new $1.68 billion nuclear fuel recycling facility that has caught the attention of big-name investors. But here's the billion-dollar question: how can a company with a potentially game-changing future be considered overvalued today? We'll uncover why Oklo (OKLO) is at the center of a tense standoff between a hyper-bullish options market and a significant camp of short sellers. With its stock chart flashing powerful technical buy signals and its long-term trend firmly up, is the story of tomorrow winning out over the valuation of today? 

Is Netflix's stock about to get canceled? 🤔 We're diving deep into the drama surrounding Netflix (NFLX), where the plot twists are getting intense. The company's fundamentals are as strong as ever, with new partnerships and a pipeline of hit content, but our analysis shows the stock may be significantly overvalued. While the options market is overwhelmingly bullish, the technical chart is flashing major warning signs of a short-term breakdown. Is this a blockbuster opportunity or a cliffhanger before a big drop? Tune in to D-Risk to find out if the streaming giant's stock can continue its rally or if its recent dip is the start of a much deeper correction.

They say in a gold rush, you sell shovels. In the AI gold rush, Super Micro Computer (SMCI) is shipping the essential hardware by the truckload—specifically, its new systems built around NVIDIA's top-of-the-line Blackwell chips. But despite this explosive fundamental news and a price that our analysis shows is undervalued, Wall Street analysts are playing it cool with a "Hold" rating, while short sellers are betting heavily against the company. This creates a tense standoff between bullish traders and a significant camp of bears, setting the stage for a potentially dramatic move. Is the company truly undervalued, or are the bears right to be cautious? Join us as we plug into the data and break down every angle of the SMCI story.

Is Microsoft's AI ambition writing checks its stock price can't cash? 🤯 In this episode of D-Risk, we dive deep into the tech giant and find a fascinating conflict between a stellar story and nervous price action. Despite a deepening partnership with OpenAI and a whopping 98% "Buy" rating from Wall Street analysts, the technical charts are flashing a different signal. The stock has lost momentum, and its short-term trend is turning negative, putting it at a critical crossroads. We'll break down the conflicting signals from bullish options traders and a very small number of short sellers, and provide a no-nonsense outlook on what's next for Microsoft. Is this a healthy pause before the next big leap, or is the AI hype starting to hit a wall? Tune in to find out where the true risk lies.

What do you do when the company you're invested in becomes the star of a potential blockbuster merger? 🎬 In this episode of D-Risk, we pull back the curtain on Warner Bros. Discovery (WBD), analyzing the fallout from a reported acquisition bid that sent the stock soaring. We'll examine the conflicting signals—from a massive surge in volume and wildly bullish options traders to technical warnings of an overbought market—to determine if this is a breakout with staying power or just a speculative sugar rush. Tune in to discover our strategic outlook and the key price levels to watch as WBD's high-stakes drama unfolds.

What does a billion-dollar bet on the future cost you today? ⚡️ In this episode of D-Risk, we dissect Chinese EV powerhouse NIO, a company at a fascinating crossroads. While strong demand for its new ES8 SUV and a long-term bullish trend signal potential, the company just announced a massive $1 billion share sale at a steep discount, creating a tug-of-war between promise and reality. We'll break down the conflicting signals—from hyper-bullish options traders to a huge contingent of short sellers—and analyze the technicals to give you a clear, no-nonsense outlook. Is this a growth story on the verge of a breakout, or a cautionary tale of a company burning cash? Tune in to find out where the true risk lies.

With its blockbuster earnings report just hours away, Adobe (ADBE) is a stock coiled for a massive move, and in this episode, we break down the critical pre-earnings setup. We explore the powerful conflict at the heart of this tech giant: a fundamental valuation that suggests the stock could be profoundly undervalued—potentially worth more than double its current price—clashing with an ugly, long-term bearish trend on the charts. As the options market signals complete indecision and the stock's price consolidates with flat momentum, we analyze whether the company's new AI catalyst will fuel a breakout or if the newly emerging bears are right to be concerned. Listen now to understand the key levels and a verdict on whether Adobe is a masterpiece priced like a sketch or if the picture is about to get much uglier.

Is Arm Holdings a high-flying tech champion or a dangerously overvalued ticking time bomb? In this episode, we dissect the chip designer at the heart of the AI revolution, which is soaring on game-changing product news and an overwhelmingly bullish technical chart. We expose the massive conflict at the core of this stock: a flawless growth story and powerful momentum clashing with a valuation so extreme that some models suggest it's profoundly overpriced. With fast-money options traders piling into bullish bets while a significant number of short-sellers are actively betting on a collapse, we break down the data to ask the ultimate question: should you ride the unstoppable trend or run from the terrifying price tag?

Can a single piece of news justify a stock's overnight explosion from a forgotten penny play to the talk of Wall Street? In this episode, we dive deep into Wearable Devices (WLDS), a company building futuristic gesture-control technology that just secured a game-changing U.S. patent, causing its stock to skyrocket on monumental volume. We unravel the core conflict facing investors: a powerful, narrative-changing catalyst versus a balance sheet still operating at a net loss and a valuation that was already considered stretched before the massive surge. With the technical chart now screaming "overbought" and signaling extreme volatility, we analyze whether this buying frenzy is the start of a new era for the company or if this rocket is dangerously overextended and about to fall back to Earth.

In an economy showing clear signs of sickness, can a healthcare giant like UnitedHealth (UNH) remain the picture of health? The company just received a massive fundamental boost from stellar Medicare ratings, fueling a frenzy among Wall Street analysts and options traders who are overwhelmingly bullish. This optimism, however, clashes with conflicting valuation models and technical charts that are flashing both a powerful buy signal and a critical "overbought" warning. In this episode, we dissect the data to determine if UNH's internal strength is enough to fight off a recessionary headwind or if this rally is about to run into a wall. Tune in for our final verdict and the key price levels that could decide the stock's fate.